Histamine, leukotriene C4 and interleukin-2 increase antibody uptake into a human carcinoma xenograft model.

por Hennigan, T. W., Begent, R. H., Allen-Mersh, T. G.
Publicado 1991

A serum factor with potential as a tumour marker in malignant lymphoma.

por Begent, R. H., Tucker, D. F., Keen, J.
Publicado 1980

Identification of PEG-precipitable serum factor associated with malignant lymphoma as C-reactive protein.

por Walker, L. C., Tucker, D. F., Begent, R. H.
Publicado 1983

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.

por Ledermann, J. A., Begent, R. H., Bagshawe, K. D.
Publicado 1988

Tumour-marker levels and prognosis in malignant teratoma of the testis.

por Germa-Lluch, J. R., Begent, R. H., Bagshawe, K. D.
Publicado 1980

Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome

por Boxer, G, Stuart-Smith, S, Flynn, A, Green, A, Begent, R
Publicado 1999

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma.

por Begent, R. H., Bagshawe, K. D., Green, A. J., Searle, F.
Publicado 1987

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.

por Boxer, G. M., Abassi, A. M., Pedley, R. B., Begent, R. H.
Publicado 1994

Circulating immune complexes as markers of response to chemotherapy in malignant teratomas and gestational trophoblastic tumours.

por Begent, R. H., Chester, K. A., Walker, L. C., Tucker, D. F.
Publicado 1982

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.

por Pedley, R. B., Boden, J. A., Boden, R., Dale, R., Begent, R. H.
Publicado 1993

Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.

por Marshall, D., Pedley, R. B., Boden, J. A., Boden, R., Begent, R. H.
Publicado 1994

Chemotherapy of advanced malignant teratomas.

por Newlands, E. S., Begent, R. H., Kaye, S. B., Rustin, G. J., Bagshawe, K. D.
Publicado 1980

The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.

por Crawford, S. M., Newlands, E. S., Begent, R. H., Rustin, G. J., Bagshawe, K. D.
Publicado 1989

Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy.

por Long, M. G., Boultbee, J. E., Langley, R., Newlands, E. S., Begent, R. H., Bagshawe, K. D.
Publicado 1992

Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

por Marshall, D., Pedley, R. B., Melton, R. G., Boden, J. A., Boden, R., Begent, R. H.
Publicado 1995

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.

por Marshall, D., Pedley, R. B., Boden, J. A., Boden, R., Melton, R. G., Begent, R. H.
Publicado 1996

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

por Hitchins, R. N., Newlands, E. S., Smith, D. B., Begent, R. H., Rustin, G. J., Bagshawe, K. D.
Publicado 1989

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice

por Violet, J A, Dearling, J L J, Green, A J, Begent, R H J, Pedley, R B
Publicado 2008

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments

por Casey, J L, Pedley, R B, King, D J, Green, A J, Yarranton, G T, Begent, R H J
Publicado 1999

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.

por Smith, D. B., Newlands, E. S., Spruyt, O. W., Begent, R. H., Rustin, G. J., Mellor, B., Bagshawe, K. D.
Publicado 1990